GHRP-6
← Back to LibraryOverview
Route(s): Subcutaneous
Typical vial sizes: 5, 10 mg
Dosing window: Pre-Meal
Receptor / target: GHS-R1a
Properties: GH Secretagogue
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mcg 3x Daily | AM Upon Waking, Mid-Day, PM Before Bedtime. Administered 30 mins before meals to maximize appetite increase. |
| Weeks 3-4 | 200 mcg 3x Daily | AM Upon Waking, Mid-Day, PM Before Bedtime. Administered 30 mins before meals to maximize appetite increase. |
| Weeks 5-12 | 300 mcg 3x Daily | AM Upon Waking, Mid-Day, PM Before Bedtime. Administered 30 mins before meals to maximize appetite increase. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative 1: Performance / Muscle Growth
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 250mcg 3x Daily | AM upon waking, Post-workout, PM before bedtime. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative 2: Anti-Aging Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg 2x Daily | AM upon waking, PM before bedtime. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active malignancy: GH/IGF-1 elevation may accelerate tumor growth.
- History of pituitary tumor or pituitary adenoma.
- Individuals struggling with weight management, obesity, or binge eating disorders: extreme ghrelin-mediated hunger will make caloric control nearly impossible.
- Eating disorders (anorexia nervosa, bulimia, binge eating disorder): extreme hunger stimulation is dangerous in these populations.
- Uncontrolled diabetes mellitus or severe insulin resistance: GH elevation worsens glucose metabolism.
- Diabetic ketoacidosis.
- History of prolactinoma or elevated prolactin: GHRP-6 significantly elevates prolactin.
- High baseline cortisol or adrenal insufficiency: additive HPA axis stimulation from cortisol-elevating mechanism.
- Anxiety disorders or high-stress baseline: cortisol elevation amplifies anxiety response.
- Concurrent use with ipamorelin or GHRP-2: receptor competition; do not stack two GHRPs.
- Concurrent use with HGH 191aa: redundant GH axis overstimulation.
- Concomitant high-dose glucocorticoids: attenuates GH response and amplifies cumulative cortisol load.
- Concomitant GLP-1 receptor agonists where appetite conflict is clinically significant: the extreme hunger from GHRP-6 directly counteracts GLP-1 appetite suppression.
- Pregnancy: safety not established.
- Breastfeeding: safety not established.
- Known hypersensitivity to GHRP-6 or excipients.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Extreme, uncontrollable hunger: the defining and most clinically significant adverse effect; onset within 15-20 minutes of injection; the most intense appetite stimulation of any compound in this database; described as urgent, compulsive, ghrelin-mediated hunger drive.
- Significant cortisol elevation: most pronounced cortisol increase among the GHRPs; transient per injection but cumulative with multi-daily dosing.
- Significant prolactin elevation: elevated via GHS-R1a activation on pituitary lactotrophs; chronic elevation increases gynecomastia risk in men and may cause menstrual irregularities.
- ACTH elevation: adrenocorticotrophic hormone released alongside cortisol via HPA axis activation.
- Water retention and peripheral edema: GH-mediated sodium and fluid retention; pronounced at 3x daily protocols.
- Head rush and transient flushing: acute GH pulse-induced vasodilation.
- Joint stiffness and arthralgia.
- Tingling or numbness in extremities.
- Vivid dreams: GH elevation during nocturnal sleep.
- Lethargy post-injection: associated with the GH pulse.
- Headache.
- Injection site irritation.
- Insulin resistance: GH elevation at 3x daily protocols; monitor fasting glucose.
- Potential for significant weight gain if caloric intake is not managed: extreme appetite stimulation can easily produce caloric surplus that exceeds the lean mass benefit.
- Receptor desensitization with extended cycles: less rapid than hexarelin but present; requires 2-4 week washout after 6-12 week cycles.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: